View
99
Download
10
Category
Preview:
DESCRIPTION
PB. Ctrl. PB. Ctrl 4h 8h 24h. 17KD. H3 AcK9-14. b -actin. 43 KD. 120. 100. 80. 60. 40. 20. 0. Supplementary figure 1. A. b III Tubulin. F actin. Hoechst. *. B. Average neurite length/cell (µm). Ctrl. PB. C. **. 160. *. 140. - PowerPoint PPT Presentation
Citation preview
Supplementary figure 1
C.
B.
H3 AcK9-14
-actin43 KD
17KD
Ctrl 4h 8h 24h
PB
Ave
rage
neu
rite
leng
th/c
ell (
µm
) *
** **
020406080
100120140160
Ctrl TSA dbcAMP Ctrl dbcAMPTSA
Actinomycin D
**
A.
0
20
40
60
80
100
120
Ctrl PB
*
Ave
rage
neu
rite
leng
th/c
ell (
µm
)Ctrl PB
F actin III Tubulin Hoechst
**
Supplementary figure 2
A.
B.
TSACtrl
TSACtrl
β III TubulinHoechst
β III TubulinHoechst
dbcAMP
0
20
40
60
80
100
120
Ctrl TSA PB
Ave
rage
neu
rite
leng
th/c
ell (
µm
)
Supplementary figure 3
A.
B.
Ave
rage
neu
rite
leng
th/c
ell (
µm
)
0
20
40
60
80
100
120
Actinomycin D Flavopiridol
CtrlTSA*
**
****
**
C.
actin43 KD
H3 AcK9-1417 KD
PDL
Mye
lin
Supplementary figureSupplementary figure 4
RNAi CBP
RNAi P/CAF
RNAi p300
0
20
40
60
80
100
120R
T-P
CR
- ar
bitr
ary
units
A.
B.
Hoechst
GFP
CBP
Hoechst
GFP
P/CAF
GFP-Scr GFP-ScrCBP-p300 siRNA P/CAF shRNA
GFP-Scr+TSA 1ng/ml
GFP-Scr+TSA 1ng/ml
CBP-p300 siRNA+TSA 1ng/ml
P/CAF shRNA+TSA 1ng/ml
C.
Hoechst
GFP
CBP
Hoechst
GFP
P/CAF
Supplementary figure 4
0
20
40
60
80
100
120
** ****
**
Pix
el in
tent
iy.-
arbi
trar
y un
its
vehicle TSA
Ctrl
CBP/p300 siRNA
P/CAF shRNA
Supplementary figure 4
D.
GFP-Scr CBP-p300 siRNA P/CAF shRNA
Hoechst
GFP
H3 AcK9-14GFP-Scr+TSA 1ng/ml
CBP-p300 siRNA+TSA 1ng/ml
P/CAF shRNA+TSA 1ng/ml
E.
F.%
of t
rans
fect
ed n
euro
ns w
ith a
popt
otic
feat
ures
(f
ragm
ente
d or
pic
notic
nuc
lei)
0
10
20
30
40
50
GFP
-scr
CB
P/p
300
siR
NA
P/C
AF
shR
NA
Supplementary figure 4
G.
0
10
20
30
40
50
% o
f tra
nsfe
cted
neu
rons
with
cle
aved
Cap
spas
e 3
stai
ning
GFP
-scr
CB
P/p
300
siR
NA
P/C
AF
shR
NA
Supplementary figure 5
CBPAcH3 K9-14 Hoechst
A.
B.
0
20
40
60
80
100
120
Ctrl TSA
CtrlTSA
**
Arb
itrar
y U
nits
0
20
40
60
80
100
120
140
High Low
Arb
itrar
y U
nits
**
TSA
AcH3K9-14
0
10
20
30
40
50
60
70
80
High Low
Ave
rage
neu
rite
leng
th/c
ell
**
TSA
AcH3K9-14
p300AcH3 K9-14 Hoechst
C. D.
Supplementary figure 6
A.
p53 putative binding site
Trans. starting site
SCG-10
Chl1
L1cam
CAP-23
Lgals1
Tub1a
+1
+1
+1
+1
+1
+1
-4000 -5000 -3000 -2000 -1000
CAP 23
0
1
2
3
4
Ctrl 4h 8h 24h
Lcam1
Lgals1
SCG10
Chl1
0
1
2
3
4
Ctrl 4h 8h 24h
*
0
1
2
3
4
Ctrl 4h 8h 24h
0
1
2
3
4
Ctrl 4h 8h 24h
****
0
1
2
3
4
Ctrl 4h 8h 24h
**
*
0
1
2
3
4
Ctrl 4h 8h 24h
**
*
Supplementary figure 6
B.F
old
chan
ge T
SA
/ ve
hicl
eF
old
chan
ge T
SA
/ ve
hicl
eF
old
chan
ge T
SA
/ ve
hicl
e
Fol
d ch
ange
TS
A /
vehi
cle
Fol
d ch
ange
TS
A /
vehi
cle
Fol
d ch
ange
TS
A /
vehi
cleTubulin 1a
Supplementary figure 7
% o
f tra
nsfe
cted
neu
rons
with
apo
ptot
ic fe
atur
es
(fra
gmen
ted
or p
ykno
tic n
ucle
i)
0
10
20
30
40
50
GFP
p53
K-R
A.
B.
0
10
20
30
40
50
GFP
p53
K-R
% o
f tra
nsfe
cted
neu
rons
with
cle
aved
activ
e ca
spas
e 3
posi
tive
cells
Recommended